A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)

A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension

A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.

Inclusion Criteria:

• Obese patients with a body mass index between 30 kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43 kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia, and sleep apnea

Exclusion Criteria:

• Patients with serious or unstable current or past medical conditions